Abelacimab for Acute Pulmonary Embolism: Translating Dual FXI/XIa Inhibition from Mechanism to Clinical Prospects
Acute pulmonary embolism (PE) remains a life-threatening condition. A critical therapeutic dilemma exists for a significant proportion of patients at high bleeding risk（approximately 30%-50%）. For these patients, anticoagulation is the mainstay, but the use of conventional agents (warfarin, DOACs, h...
| Published in: | Clinical and Applied Thrombosis/Hemostasis |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-10-01
|
| Online Access: | https://doi.org/10.1177/10760296251386036 |